David John Rowlands
Wellcome Trust
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by David John Rowlands.
Gene | 1985
Susan E. Newton; Anthony R. Carroll; Richard O. Campbell; Berwyn E. Clarke; David John Rowlands
The nucleotide sequence of foot-and-mouth disease virus (FMDV) RNA to the 5 side of the poly(C) tract (S fragment) has been determined for representatives of the A and O serotypes of the virus. The two S fragments differ in length by five nucleotides (nt), with 367 nt for O1 compared with 362 nt for A10, due to a number of insertions/deletions. However, the two sequences show 86% homology. There are no conserved open reading frames (ORFs). Secondary structure predictions reveal a high degree of potential base-pairing, such that the entire S fragment sequence can be folded into a hairpin structure.
Molecular Immunology | 1992
Anthony R. Carroll; David John Rowlands; Berwyn E. Clarke
A humanized rat monoclonal antibody (Campath 1H) has been expressed in HeLa cells using recombinant vaccinia viruses. Heavy and light chain recombinant viruses were constructed separately and when grown independently produced proteins of the expected molecular weights. Expressed heavy chain was entirely intracellular but light chain was mainly excreted and processed. When cells were infected at high multiplicity with both heavy and light chain recombinants a proportion of the heavy chain was then found in the extracellular medium. This secreted heavy chain was shown to be associated with light chain as judged by co-electrophoresis in non-reducing SDS polyacrylamide gels and by co-purification on protein-A sepharose. The secreted heavy and light chain complexes were functionally active as an antibody, with activity comparable to authentic Campath 1H antibody as assessed by ELISA, T-cell binding and antigen binding assays. Production of antibody in this system was achieved in the absence of serum, which is an important consideration in the production of monoclonal antibodies (MAbs). The amount of antibody produced was 0.2-0.4 micrograms/10(6) cells without optimization of expression levels. The wide host cell range of vaccinia virus together with the recently developed methods for increasing expression levels make this an attractive candidate as a flexible general vehicle for producing MAbs.
Archive | 1990
Alan Louis Brown; Berwyn Ewart Clarke; David John Rowlands
European Journal of Immunology | 1993
Gillian Z. Hastings; Michael J. Francis; David John Rowlands; Benjamin M. Chain
Archive | 1992
David John Rowlands; Berwyn E. Clarke; Anthony R. Carroll
European Journal of Immunology | 1993
Gillian Z. Hastings; Michael J. Francis; David John Rowlands; Benjamin M. Chain
Archive | 1992
Stephen James; David John Rowlands; Michael J. Francis
Archive | 1995
David John Rowlands; Michael J. Francis
Archive | 1992
David John Rowlands; Berwyn E. Clarke; Anthony R. Carroll
Archive | 1990
David John Rowlands; Berwyn E. Clarke; Michael J. Francis